Fucoidan as a marine anticancer agent in preclinical development

Area of Science:

• Marine natural products
• Pharmacology
• Cancer research

Background:

• Fucoidan is a sulfated polysaccharide from brown seaweed, available as a supplement.
• In vitro studies show fucoidan possesses antiproliferative, antiangiogenic, and anticancer properties.
• Fucoidan's anticancer effects vary by structure and can target tumor and immune cells.

Purpose of the Study:

• To review the in vivo effects of fucoidan on tumor growth, angiogenesis, and immune response.
• To assess the applicability of in vitro findings to preclinical development.
• To evaluate fucoidan's potential as a marine anticancer drug.

Main Methods:

• Review of preclinical studies involving systemic and local fucoidan administration.
• Analysis of data from animal tumor models.
• Comparison of in vitro and in vivo outcomes.

Main Results:

• Fucoidan demonstrates varied effects on tumor growth and angiogenesis in vivo.
• Immune reactions are modulated by fucoidan administration.
• In vitro results suggest potential, but in vivo validation is crucial.

Conclusions:

• Fucoidan exhibits promising anticancer properties in vitro, with low toxicity.
• Further in vivo studies are essential for developing fucoidan as a marine anticancer therapeutic.
• Translating in vitro findings to effective in vivo applications requires rigorous investigation.